HER2-driven breast cancer suppression by the JNK signaling pathway
Identified with Open Access button
Raju Ponny, S.
Muller, W. J.
Davis, R. J.
AffiliationProgram in Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605
MetadataShow full item record
AbstractThe HER2+ subtype of human breast cancer is associated with the malignant transformation of luminal ductal cells of the mammary epithelium. The sequence analysis of tumor DNA identifies loss of function mutations and deletions of the MAP2K4 and MAP2K7 genes that encode direct activators of the JUN NH2-terminal kinase (JNK). We report that in vitro studies of human mammary epithelial cells with CRISPR-induced mutations in the MAPK and MAP2K components of the JNK pathway caused no change in growth in 2D culture, but these mutations promoted epithelial cell proliferation in 3D culture. Analysis of gene expression signatures in 3D culture demonstrated similar changes caused by HER2 activation and JNK pathway loss. The mechanism of signal transduction cross-talk may be mediated, in part, by JNK-suppressed expression of integrin α6β4 that binds HER2 and amplifies HER2 signaling. These data suggest that HER2 activation and JNK pathway loss may synergize to promote breast cancer. To test this hypothesis, we performed in vivo studies using a mouse model of HER2+ breast cancer with Cre/loxP-mediated ablation of genes encoding JNK (Mapk8 and Mapk9) and the MAP2K (Map2k4 and Map2k7) that activate JNK in mammary epithelial cells. Kaplan-Meier analysis of tumor development demonstrated that JNK pathway deficiency promotes HER2+-driven breast cancer. Collectively, these data identify JNK pathway genes as potential suppressors for HER2+ breast cancer.
CitationItah Z, Chaudhry S, Raju Ponny S, Aydemir O, Lee A, Cavanagh-Kyros J, et al. HER2-driven breast cancer suppression by the JNK signaling pathway. Proceedings of the National Academy of Sciences of the United States of America. 2023 Jan 24;120(4):e2218373120. PubMed PMID: 36656864. Epub 2023/01/20. eng.
JournalProceedings of the National Academy of Sciences U S A
- c-Jun N-terminal kinase activity supports multiple phases of 3D-mammary epithelial acinus formation.
- Authors: McNally S, McArdle E, Gilligan E, Napoletano S, Gajewska M, Bergin O, McCarthy S, Whyte J, Bianchi A, Stack J, Martin F
- Issue date: 2011
- MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
- Authors: Chen J, Miller EM, Gallo KA
- Issue date: 2010 Aug 5
- The cJUN NH(2)-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation.
- Authors: Girnius N, Edwards YJ, Garlick DS, Davis RJ
- Issue date: 2018 Jun 1
- Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
- Authors: Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC Jr
- Issue date: 2007 Nov
- HER2 drives Mucin-like 1 to control proliferation in breast cancer cells.
- Authors: Conley SJ, Bosco EE, Tice DA, Hollingsworth RE, Herbst R, Xiao Z
- Issue date: 2016 Aug 11